OBJECTIVE: To describe the management of a population of human immunodeficiency virus (HIV)-infected pregnant women in Latin America and the Caribbean, and to assess factors associated with maternal viral load of 1,000 copies/mL or more and with infant HIV-1 infection. METHODS: Eligibility criteria were enrollment in the prospective cohort study as of March 2006; delivery of a liveborn, singleton infant; and completion of the 6-month postpartum or postnatal visit. RESULTS: Of 955 women enrolled in Argentina, the Bahamas, Brazil, and Mexico, 770 mother-infant pairs were eligible. At enrollment, most women were relatively healthy (87% asymptomatic, 59% with viral load less than 1,000 copies/mL, 62% with CD4(+)% of 25% or more). Most (99%) received antiretrovirals during pregnancy (56% prophylaxis, 44% treatment), and 38% delivered by cesarean before labor and before ruptured membranes. Only 18% of women had a viral load of 1,000 copies/mL or more after delivery (associated in adjusted analyses with receipt of antiretrovirals at conception, CD4(+)% [lower], viral load [higher], and country at enrollment, enrollment late in pregnancy, and inversely related to antiretroviral regimen [two nucleoside or nucleotide analogue reverse transcriptase inhibitors plus one nonnucleoside reverse transcriptase inhibitor] during pregnancy). None of the infants breastfed, and all received antiretroviral prophylaxis. Seven infants became infected (0.91%; 95% confidence interval 0.37-1.86). Low birth weight infants and those whose mothers had a low CD4(+)% at hospital discharge after delivery and were not receiving antiretrovirals at enrollment were at higher risk of HIV infection. CONCLUSION: Only a minority of women had a viral load of 1,000 copies/mL or more around delivery, and mother-to-child transmission of HIV occurred rarely (1%).
OBJECTIVE: To describe the management of a population of human immunodeficiency virus (HIV)-infected pregnant women in Latin America and the Caribbean, and to assess factors associated with maternal viral load of 1,000 copies/mL or more and with infantHIV-1 infection. METHODS: Eligibility criteria were enrollment in the prospective cohort study as of March 2006; delivery of a liveborn, singleton infant; and completion of the 6-month postpartum or postnatal visit. RESULTS: Of 955 women enrolled in Argentina, the Bahamas, Brazil, and Mexico, 770 mother-infant pairs were eligible. At enrollment, most women were relatively healthy (87% asymptomatic, 59% with viral load less than 1,000 copies/mL, 62% with CD4(+)% of 25% or more). Most (99%) received antiretrovirals during pregnancy (56% prophylaxis, 44% treatment), and 38% delivered by cesarean before labor and before ruptured membranes. Only 18% of women had a viral load of 1,000 copies/mL or more after delivery (associated in adjusted analyses with receipt of antiretrovirals at conception, CD4(+)% [lower], viral load [higher], and country at enrollment, enrollment late in pregnancy, and inversely related to antiretroviral regimen [two nucleoside or nucleotide analogue reverse transcriptase inhibitors plus one nonnucleoside reverse transcriptase inhibitor] during pregnancy). None of the infants breastfed, and all received antiretroviral prophylaxis. Seven infants became infected (0.91%; 95% confidence interval 0.37-1.86). Low birth weight infants and those whose mothers had a low CD4(+)% at hospital discharge after delivery and were not receiving antiretrovirals at enrollment were at higher risk of HIV infection. CONCLUSION: Only a minority of women had a viral load of 1,000 copies/mL or more around delivery, and mother-to-child transmission of HIV occurred rarely (1%).
Authors: Marisa M Mussi-Pinhata; Fabrizio Motta; Laura Freimanis-Hance; Ricardo de Souza; Edgardo Szyld; Regina C M Succi; Celia D C Christie; Maria J Rolon; Mariana Ceriotto; Jennifer S Read Journal: Int J Infect Dis Date: 2010-05-08 Impact factor: 3.623
Authors: Jennifer S Read; Geraldo Duarte; Laura Freimanis Hance; Jorge Pinto; Maria I Gouvea; Rachel A Cohen; Breno Santos; Elizabete Teles; Regina Succi; Jorge Alarcon; Sonia K Stoszek Journal: Int J Epidemiol Date: 2011-02-27 Impact factor: 7.196
Authors: R Kreitchmann; S X Li; V H Melo; D Fernandes Coelho; D H Watts; E Joao; C M Coutinho; J O Alarcon; G K Siberry Journal: BJOG Date: 2014-03-07 Impact factor: 6.531
Authors: Alicen B Spaulding; Qilu Yu; Lucy Civitello; Marisa M Mussi-Pinhata; Jorge Pinto; Ivete M Gomes; Jorge O Alarcón; George K Siberry; D Robert Harris; Rohan Hazra Journal: AIDS Res Hum Retroviruses Date: 2016-04 Impact factor: 2.205
Authors: Elizabeth Stankiewicz Machado; Margot R Krauss; Karen Megazzini; Conrado Milani Coutinho; Regis Kreitchmann; Victor Hugo Melo; José Henrique Pilotto; Mariana Ceriotto; Cristina B Hofer; George K Siberry; D Heather Watts Journal: J Infect Date: 2014-01-23 Impact factor: 6.072
Authors: Regis Kreitchmann; Karen Megazzini; Victor Hugo Melo; Débora Fernandes Coelho; D Heather Watts; Margot Krauss; Maria Isabel Gouvea; Geraldo Duarte; Marcelo H Losso; George K Siberry Journal: AIDS Care Date: 2015-08-19
Authors: Maria Letícia S Cruz; D Robert Harris; Jennifer S Read; Marisa M Mussi-Pinhata; Regina C M Succi Journal: Nutr Res Date: 2007-11 Impact factor: 3.315
Authors: J S Read; B M Best; A M Stek; C Hu; E V Capparelli; D T Holland; S K Burchett; M E Smith; E C Sheeran; W T Shearer; I Febo; M Mirochnick Journal: HIV Med Date: 2008-09-14 Impact factor: 3.180